Kaken Pharmaceutical (4521) Fundamentals 2026 — P/E 68.8x, Revenue Analysis | SniperIQ
Kaken Pharmaceutical (4521) is a JP-listed Healthcare company in Drug Manufacturers - Specialty & Generic with a market capitalization of ¥147.3B, trading at ¥3890.00 on the JPX. This SniperIQ fundamentals page covers Kaken Pharmaceutical's valuation (P/E 68.8x, P/B 1.0x), profitability (net margin 2.8%), revenue (¥76.9B in FY2026), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Kaken Pharmaceutical's market cap?
Kaken Pharmaceutical (4521) has a market capitalization of approximately ¥147.3B, trading at ¥3890.00 on the JPX. Market cap moves with the live share price.
What is Kaken Pharmaceutical's P/E ratio?
Kaken Pharmaceutical's trailing twelve-month P/E ratio is 68.8x, with a price-to-book (P/B) of 1.0x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Kaken Pharmaceutical?
Kaken Pharmaceutical runs a net profit margin of 2.8%, a gross margin of 52.0%, and an operating margin of -1.2%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Kaken Pharmaceutical generate?
Kaken Pharmaceutical reported revenue of ¥76.9B for fiscal year 2026, with net income of ¥2.1B and earnings per share (EPS) of 56.55. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Kaken Pharmaceutical pay a dividend?
Kaken Pharmaceutical offers a trailing dividend yield of about 4.9%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Kaken Pharmaceutical financially healthy?
Kaken Pharmaceutical carries a debt-to-equity ratio of 0.03x and a current ratio of 4.52x, with a market beta of 0.13. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Kaken Pharmaceutical a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Kaken Pharmaceutical (4521) the key facts are: market cap ¥147.3B, P/E 68.8x, revenue ¥76.9B, 52-week range 3540-4445. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Kaken Pharmaceutical's full fundamentals live
Get Kaken Pharmaceutical's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.